The conversation happens in cardiology and internal medicine clinics across India every day. A patient, often in their 40s or early 50s, presents with elevated LDL cholesterol and triglycerides at their annual blood test. They insist they’ve been careful with their diet. Their weight is in the normal or borderline range. The doctor prescribes a statin, advises dietary changes, and schedules a follow-up in three months.<\/p>\n
Three months later, the LDL has come down \u2014 the statin is working. But the triglycerides are still elevated, the HDL is still low, and the patient’s visceral fat continues to accumulate invisibly, driving the same metabolic dysfunction that elevated the cholesterol in the first place.<\/p>\n
The statin treated the number. It didn’t treat the cause. And in a significant proportion of cases, the cause is body composition \u2014 specifically, visceral fat.<\/p>\n
Dyslipidemia \u2014 abnormal blood lipid levels \u2014 has reached epidemic proportions in India. According to ICMR data, 25-30% of urban Indians have abnormal lipid profiles<\/strong>. A 2021 population study across six Indian cities found that elevated total cholesterol affected 13.9% of the urban adult population, while borderline high cholesterol (160-199 mg\/dL) affected an additional 29.5%. Elevated triglycerides \u2014 which are particularly linked to visceral fat \u2014 were found in 29.5% of participants.<\/p>\n These numbers have increased substantially over the last 20 years and show no sign of stabilising. India’s cardiologists are now treating dyslipidemia in patients in their early 30s at rates that would have been unusual a generation ago.<\/p>\n Understanding why requires understanding a mechanism that most patients \u2014 and some physicians \u2014 don’t fully appreciate: the direct metabolic link between visceral fat and lipid abnormalities.<\/p>\n There is a fundamental distinction between subcutaneous fat (the fat under your skin, the fat you can pinch) and visceral fat (the fat stored around your abdominal organs \u2014 liver, intestines, pancreas). Subcutaneous fat is relatively inert metabolically. Visceral fat is highly metabolically active. This distinction matters enormously for cardiovascular risk.<\/p>\n Visceral adipose tissue continuously releases free fatty acids (FFAs) directly into the portal venous circulation \u2014 the blood supply that drains directly into the liver. This creates a constant flux of FFAs arriving at the liver that the organ must process. The liver responds to elevated FFA influx in several unfavourable ways.<\/p>\n When the liver receives a constant high load of free fatty acids from visceral fat via portal blood, it responds by:<\/p>\n This is why a person with high visceral fat will typically show a lipid profile characterised by: elevated LDL, elevated triglycerides, and low HDL \u2014 the classic atherogenic lipid pattern. And this is why the same person may eat a relatively careful diet and still have persistently abnormal lipids: the dietary contribution to cholesterol is being overwhelmed by the continuous metabolic activity of accumulated visceral fat.<\/p>\n Visceral fat also secretes inflammatory cytokines \u2014 TNF-alpha, IL-6, and others \u2014 that further impair lipid metabolism and promote endothelial dysfunction. The ECW\/TBW ratio on an InBody test, when elevated above 0.380, reflects this systemic inflammatory state. This is one reason why elevated ECW\/TBW values in a body composition assessment should not be ignored \u2014 they may be a window into the same inflammatory process that is driving both visceral fat accumulation and lipid abnormalities.<\/p>\n One of the most clinically important and underappreciated phenomena in Indian cardiology is the frequency of significant dyslipidemia in individuals with normal or near-normal BMI. Indian physicians see this constantly \u2014 a patient with a BMI of 22-24, apparently normal weight, presenting with triglycerides of 250 mg\/dL and LDL of 160 mg\/dL. It seems contradictory until you understand visceral fat distribution.<\/p>\n Indians, due to a combination of genetic predisposition, dietary pattern, and activity levels, have a well-documented tendency to preferentially accumulate visceral fat relative to subcutaneous fat \u2014 even at normal body weight. This is the “thin-fat” Indian phenotype. A person with a VFA (Visceral Fat Area) of 130-140 cm\u00b2 can have a BMI of 23 and no visible abdominal obesity. Their cholesterol, however, will reflect the metabolic reality of that visceral fat load.<\/p>\n A 2020 study in the Journal of Association of Physicians of India<\/em> found that Indian adults with VFA above 100 cm\u00b2 \u2014 as measured by body composition analysis \u2014 had a 2.8-fold higher odds of atherogenic dyslipidemia compared to those with VFA below 80 cm\u00b2, independent of BMI. The VFA measurement explained metabolic risk that BMI could not.<\/p>\n To be clear: statins are effective, evidence-based medicines and are genuinely life-saving for patients with established cardiovascular disease, very high LDL, familial hypercholesterolaemia, or multiple risk factors. This article is not arguing against statin use where it is clinically indicated.<\/p>\n What statins do not do is reduce visceral fat. A patient on a statin whose VFA remains at 150 cm\u00b2 has lower LDL numbers on their next blood test, but their portal circulation is still flooded with free fatty acids from visceral fat. Their triglycerides remain elevated. Their HDL remains low. Their cardiovascular risk \u2014 beyond LDL \u2014 is substantially unchanged. The statin has treated a downstream marker without addressing the upstream source.<\/p>\n A comprehensive approach to dyslipidemia in visceral-fat-driven cases requires treating the cause, not just the number.<\/p>\n Indian cardiologists and metabolic physicians are increasingly using the Triglyceride:HDL ratio<\/strong> as a more sensitive cardiovascular risk marker than LDL cholesterol alone \u2014 particularly for the Indian population. A ratio above 3.5 (using mg\/dL units) is associated with elevated cardiovascular risk and is a strong indicator of insulin resistance and visceral fat excess.<\/p>\n This ratio is highly responsive to visceral fat reduction. When VFA decreases \u2014 through the interventions described below \u2014 triglycerides fall, HDL rises, and the ratio improves substantially. This improvement reflects a genuine reduction in metabolic risk, not just a medication-induced number change.<\/p>\n Research provides specific guidance on the relationship between VFA reduction and lipid improvement. A landmark study in the International Journal of Obesity<\/em> found that:<\/p>\n In practical terms: if your InBody test shows VFA of 150 cm\u00b2, a reduction to 120-125 cm\u00b2 \u2014 a 15-17% decrease \u2014 could substantially improve your triglyceride:HDL ratio, potentially reducing or eliminating the need for lipid-lowering medication in cases where statins are being used primarily for borderline-elevated values.<\/p>\n Meta-analyses consistently find that resistance training is more effective than aerobic exercise alone for reducing visceral fat. A 2022 review in Obesity Reviews<\/em> found that progressive resistance training (3 sessions per week, 45-60 minutes per session, over 12 weeks) reduced VFA by an average of 12-16% in previously sedentary adults, without significant dietary change. For Indian adults, where gym culture and structured resistance training have been historically less prevalent than in Western populations, this represents an underutilised lever for metabolic health improvement.<\/p>\n For lipid management in India, dietary interventions with the strongest evidence for VFA reduction include:<\/p>\n The power of InBody testing for managing dyslipidemia lies in tracking body composition changes alongside blood lipid measurements. A patient who can watch their VFA decrease from 145 cm\u00b2 to 120 cm\u00b2 over 12 weeks \u2014 while seeing triglycerides fall on their blood test \u2014 has visible, motivating evidence that their lifestyle changes are working at the metabolic level. This feedback loop is a powerful driver of sustained behaviour change.<\/p>\n The InBody Score, which integrates both muscle and fat metrics, provides a single number that trends upward as the programme works \u2014 an intuitive progress indicator that most patients find more motivating than a list of blood values.<\/p>\n The body composition approach to dyslipidemia is not a replacement for medical management when it is clinically required. Statins are necessary and appropriate when:<\/p>\n In these situations, statins and body composition improvement work synergistically. The statin reduces LDL; the VFA reduction improves triglycerides and HDL and reduces systemic inflammation. Together, they produce better cardiovascular risk reduction than either intervention alone.<\/p>\nThe Biology: How Visceral Fat Drives Dyslipidemia<\/h2>\n
Visceral Fat Is Not Inert Storage<\/h3>\n
The Portal Circulation Pathway to High Cholesterol<\/h3>\n
\n
Inflammation as an Amplifier<\/h3>\n
Why the “Normal Weight, High Cholesterol” Pattern Is So Common in Indians<\/h2>\n
What Statins Do \u2014 and Don’t Do<\/h2>\n
The Triglyceride:HDL Ratio \u2014 A Better Risk Marker Than LDL Alone<\/h2>\n
How Much VFA Reduction Is Needed \u2014 and What It Does to Lipids<\/h2>\n
\n
The Body Composition Approach to Managing Cholesterol<\/h2>\n
Resistance Training \u2014 The Most Effective VFA Reducer<\/h3>\n
Diet: The Indian Context<\/h3>\n
\n
Monitoring Progress With InBody<\/h3>\n
When Statins Are Genuinely Necessary<\/h2>\n
\n
Know Your Visceral Fat \u2014 Before Your Lipid Panel Does the Talking<\/h2>\n